Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes

Affiliations

• ¹ Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland, USA.
• ² Weight Control and Diabetes Research Center, The Miriam Hospital, Providence, Rhode Island, USA.
• ³ Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
• ⁴ Department of Nutritional Sciences, Texas Tech University, Lubbock, Texas, USA.
• ⁵ General Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA.
• ⁶ Pennington Biomedical Research Center, LSU System, Baton Rouge, Louisiana, USA.